-
摘要: 肺癌是最常见的恶性肿瘤之一,30%发生于70岁以上的患者,而且大多数就诊时已到中晚期而失去根治手术的机会,主要采用化疗为主的综合治疗.培美曲塞(Pemetrexed,PEM)是一种新型的多靶点抗叶酸制剂,因其良好的疗效和不良反应小,近年来在晚期非小细胞肺癌(NSCLC)的治疗中受到广泛关注[1].本文采用PEM+顺铂的联合方案治疗老年晚期NSCLC,并与吉西他滨(gemcit-abine,GEM)+顺铂方案做对照,旨在观察其疗效和安全性,现报道如下.
-
-
李树婷, 马飞, 孙燕. 抗肿瘤代谢新药-培美曲塞 [J]. 癌症进展, 2005(5):471.doi: 10.3969/j.issn.1672-1535.2005.05.013. Vogelzang NJ, Rusthoven JJ, Symanowski J. Phase Ⅲ study of peme trexed incombination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [J]. Journal of Clinical Oncology, 2003, (14):2636.doi: 10.1200/JCO.2003.11.136. 王莉. 培美曲塞治疗非小细胞肺癌 [J]. 癌症进展, 2006(5):440.doi: 10.3969/j.issn.1672-1535.2006.05.013. Hanna N, Shepherd FA, Fossella FV. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non small-cell lung cancer previously treated with chemotherapy [J]. Journal of Clinical Oncology, 2004(9):1589.doi: 10.1200/JCO.2004.08.163. Manegold C, Gatzemeier vyon, Pawel J. Front-linetreatment of advanced non-small-cell lung cancer with MTA (LY231514 pemetrexed disodium, ALIM-TA)and cisplatin:a muhicenter phaseⅡ tria1 [J]. Annals of Oncology, 2000(4):435.doi: 10.1023/A:1008336931378.
计量
- 文章访问数: 111
- HTML全文浏览量: 14
- PDF下载量: 6
下载:
苏公网安备 32100302010246号
